Chemoembolization Combined with Radiofrequency Ablation is the Best Option for the Local Treatment of Early Hepatocellular Carcinoma?

Overview

Journal Clin Mol Hepatol

Specialty Gastroenterology

Date 2023 Aug 16

PMID 37583053

Authors

Hyo-Cheol Kim

Affiliations

Soon will be listed here.

References

Thein H, Isaranuwatchai W, Qiao Y, Wong K, Sapisochin G, Chan K . Cost-effectiveness analysis of potentially curative and combination treatments for hepatocellular carcinoma with person-level data in a Canadian setting. Cancer Med. 2017; 6(9):2017-2033. PMC: 5603843. DOI: 10.1002/cam4.1119. View

Yang Y, Yu H, Qi L, Liu C, Feng Y, Qi J . Combined radiofrequency ablation or microwave ablation with transarterial chemoembolization can increase efficiency in intermediate-stage hepatocellular carcinoma without more complication: a systematic review and meta-analysis. Int J Hyperthermia. 2022; 39(1):455-465. DOI: 10.1080/02656736.2022.2048095. View

Suh Y, Choi J, Yoon J, Lee D, Kim Y, Lee J . No-Touch vs. Conventional Radiofrequency Ablation Using Twin Internally Cooled Wet Electrodes for Small Hepatocellular Carcinomas: A Randomized Prospective Comparative Study. Korean J Radiol. 2021; 22(12):1974-1984. PMC: 8628150. DOI: 10.3348/kjr.2021.0319. View

Tang C, Shen J, Feng W, Bao Y, Dong X, Dai Y . Combination Therapy of Radiofrequency Ablation and Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Retrospective Study. Medicine (Baltimore). 2016; 95(20):e3754. PMC: 4902444. DOI: 10.1097/MD.0000000000003754. View

Kim E, Sher A, Abboud G, Schwartz M, Facciuto M, Tabrizian P . Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study. Lancet Gastroenterol Hepatol. 2022; 7(9):843-850. DOI: 10.1016/S2468-1253(22)00091-7. View

Lee D, Lee M, Kim P, Lee Y, Park H, Lee J . Outcome of No-Touch Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Multicenter Clinical Trial. Radiology. 2021; 301(1):229-236. DOI: 10.1148/radiol.2021210309. View

Cho Y, Kim B, Park J . Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison. Clin Mol Hepatol. 2023; 29(2):252-262. PMC: 10121305. DOI: 10.3350/cmh.2023.0099. View

Yu Q, Thapa N, Karani K, Navuluri R, Ahmed O, Van Ha T . Transarterial Radioembolization versus Transarterial Chemoembolization Plus Percutaneous Ablation for Unresectable, Solitary Hepatocellular Carcinoma of ≥3 cm: A Propensity Score-Matched Study. J Vasc Interv Radiol. 2022; 33(12):1570-1577.e1. DOI: 10.1016/j.jvir.2022.09.005. View

Kim G, Won J, Kim M, Park S, Lee D, Shin W . Cryoablation of Hepatocellular Carcinoma with High-Risk for Percutaneous Ablation: Safety and Efficacy. Cardiovasc Intervent Radiol. 2016; 39(10):1447-54. DOI: 10.1007/s00270-016-1384-4. View

10.

Kim T, Lee J, Lee D, Joo I, Park S, Yoon J . Can "no-touch" radiofrequency ablation for hepatocellular carcinoma improve local tumor control? Systematic review and meta-analysis. Eur Radiol. 2022; 33(1):545-554. DOI: 10.1007/s00330-022-08991-1. View

11.

Cho Y, Choi J, Kwon H, Kim K, Lee B, Chu H . Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association. Clin Mol Hepatol. 2023; 29(3):521-541. PMC: 10366793. DOI: 10.3350/cmh.2023.0202. View

12.

An C, Cheng Z, Yu X, Han Z, Liu F, Li X . Ultrasound-guided percutaneous microwave ablation of hepatocellular carcinoma in challenging locations: oncologic outcomes and advanced assistive technology. Int J Hyperthermia. 2020; 37(1):89-100. DOI: 10.1080/02656736.2019.1711203. View

13.

Kim W, Cho S, Shin S, Hyun D, Lee M, Rhim H . Combination therapy of transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) for small hepatocellular carcinoma: comparison with TACE or RFA monotherapy. Abdom Radiol (NY). 2019; 44(6):2283-2292. DOI: 10.1007/s00261-019-01952-1. View

14.

. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol. 2022; 28(4):583-705. PMC: 9597235. DOI: 10.3350/cmh.2022.0294. View

15.

Kim H, An J, Han S, Shim J . Loco-regional therapies competing with radiofrequency ablation in potential indications for hepatocellular carcinoma: a network meta-analysis. Clin Mol Hepatol. 2023; 29(4):1013-1028. PMC: 10577337. DOI: 10.3350/cmh.2023.0131. View